Low Prevalence of *HNF1A* Mutations After Molecular Screening of Multiple MODY Genes in 58 Italian Families Recruited in the Pediatric or Adult Diabetes Clinic From a Single Italian Hospital

Maurizio Delvecchio,[1] *Ornella Ludovico,*[2] *Claudia Menzaghi,*[3] *Rosa Di Paola,*[3] *Leopoldo Zelante,*[4] *Antonella Marucci,*[3] *Valeria Grasso,*[5] *Vincenzo Trischitta,*[3,6] *Massimo Carella,*[4] *and Fabrizio Barbetti*[5,7]

Diabetes Care 2014;37:e258–e260 | DOI: 10.2337/dc14-1788

Maturity-onset diabetes of the young (MODY; MIM# 606391) is a genetically and clinically heterogeneous form of diabetes, accounting for 1–2% of all diabetes cases (1). MODY is characterized by mild hyperglycemia or overt diabetes usually detected in three consecutive generations, with onset before the age of 25 years and absence of type 1 diabetes autoantibodies. Among the thirteen MODY genes identified, two subtypes, *GCK*-MODY and *HNF1A*-MODY, account for most of cases (1). The prevalence of *GCK*-MODY has been reported higher in Southern Europe (2), while *HNF1A*-MODY is the most common MODY subtype in Northern Europe (3). This difference might be attributable to the clinical setting in which genetic screening is performed, especially when pediatric and adult diabetes clinics are distinct entities. We addressed this issue by investigating MODY patients identified in the pediatric or in the adult diabetes clinics of the same research-based hospital in Southern Italy to obtain data from a homogeneous geographic and genetic background. We selected 58 probands of Italian ancestry fulfilling stringent MODY criteria: *1*) blood glucose >100 mg/dL (confirmed), *2*) no type 1 diabetes autoantibodies, and *3*) three consecutive generations with hyperglycemia before age 25 years. Forty-three patients were recruited at the pediatric clinic (age 1–18 years) and 15 at the adult clinic (age >18 years). We screened by DNA sequencing six "classic" MODY genes (*HNF4A*, *GCK*, *HNF1A*, *PDX1*, *HNF1B*, *NEUROD1*) (1) in both groups and *INS* (MODY 10) and *KCNJ11* (MODY 13) genes in the pediatric group.

In the pediatric group, we identified 29 *GCK* (67.4%), 6 *HNF1A* (14%), 2 *HNF4A* (4.6%), and 2 *HNF1B* (4.6%) mutations, with only 4 children (9.3%) remaining without a genetic diagnosis (MODY X). In the adult group, we detected 2 *GCK* (13.3%) ($P < 0.001$ vs. pediatric group), 3 *HNF1A* (20%), and 1 *HNF4A* (6.7%) mutations. Nine adult patients were classified as MODY X (60%, $P < 0.001$ vs. pediatric group) (Table 1).

We thus confirmed that *GCK* mutations represent the most common MODY defect in the pediatric setting, whereas they are rare in patients from the adult diabetes clinic. *HNF1A* mutations ranked second (14%) in the pediatric clinic but accounted for a similar proportion (20%) among adults. This result was in keeping with previous data (14%) obtained in a total of 42 Italian families with autosomal dominant diabetes recruited in Central (Tuscany, Sardinia) and Northern (Piedmont) Italy (4,5), and it was in sharp contrast with results obtained in Northern Europe (3). The major strength of our investigation is that the two groups of patients were recruited from the same geographic area and screened in the same laboratory. Conversely, we acknowledge that the small number of families in the adult group represents a study limitation. Thus, these results need to be replicated before one can firmly conclude that there is a "latitude" of MODY across Europe. In all, our study confirms that *HNF1A* mutations are much less prevalent in Italy compared with Northern Europe and that this does not depend on ascertainment bias.

Acknowledgments. The following pediatricians contributed to the recruitment and to the clinical and the genetic counseling for the referred patients included in this study. They are considered coauthors: Francesco Gallo (Pediatrics Unit, Antonio Perrino Hospital, Brindisi, Italy), Maria Susanna Coccioli (Pediatrics Unit, Dario Camberlingo Hospital, Francavilla Fontana Brindisi, Italy), Clara Zecchino and Maria Felicia Faienza (Department of Biomedical Sciences and Human Oncology, Pediatrics Section, University of Bari Aldo Moro, Bari, Italy), Giuliana Cardinale (Pediatrics Unit, Francesco Ferrari Hospital,

[1]*Pediatrics Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy*
[2]*Endocrine Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy*
[3]*Research Unit of Diabetes and Endocrine Diseases, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy*
[4]*Medical Genetics Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy*
[5]*Bambino Gesù Children's Hospital, IRCCS, Rome, Italy*
[6]*Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy*
[7]*Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy*

Corresponding authors: Maurizio Delvecchio, mdelvecchio75@gmail.com, and Fabrizio Barbetti, fabrizio.barbetti@uniroma2.it.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Table 1—MODY gene mutations found in our sample

MODY gene mutated	Patients	Nucleotide change	Mutations (probands)	Age at clinical diagnosis (years)	Age at molecular screening (years)	Blood glucose (mg/dL)	HbA_{1c} (%)	Treatment at molecular diagnosis
HNF4A (NM_175914.4)	2 pediatric patients (4.6%)	c.932G>A c.340C>T	p.Arg311Hist (1) p.Arg114Trp (1)	9.2–11.8	9.9–12	103–119	5.5–6.7	None
	1 adult patient (6.7%)	c.340C>T	p.Arg114Trp (1)	20.1	66	167	9.2	OAD
GCK (NM_000162.3)	29 pediatric patients (67.4%)	c.49G>T c.146C>T§ c.175C>T c.218A>G c.401T>C c.571C>T c.667G>A c.676G>A c.683C>T c.704T>C c.793G>A c.866A>G c.1112delG§ c.1114G>T	p.Glu17Term (2) p.Thr49Ile@ (1) p.Pro59Ser (6) p.Asp73Gly (1) p.Leu134Pro (1) p.Arg191Trp (2) p.Gly223Ser (7) p.Val226Met (1) p.Thr228Met (2) p.Met235Thr (1) p.Glu265Lys (1) p.Tyr289Cys (2) p.Cys371Serfs31# (1) p.Glu372Term (1)	0.8–13.9	0.9–14.3	106–131	5.8–7.4	1 patient: diet; 28 patients: none
	2 adult patients (13.3%)	c.175C>T c.775G>A	p.Pro59Ser (1) p.Ala259Thr (1)	17.9–18.6	44–45	113–132	5.4–5.7	1 patient: diet; 1 patient: OAD
HNF1A (NM_000545.5)	6 pediatric patients (14%)	c.160C>T c.392G>A c.686G>A c.814C>T c.1061C>T c.1330_1331delCA	p.Arg54Term (1) p.Arg131Gln (1) p.Arg229Gln (1) p.Arg272Cys (1) p.Thr354Met (1) p.Gln444Glufs*104 (1)	14.1–17.8	14.2–19.1	109–149	5.9–8.1	3 patients: none; 2 patients: insulin; 1 patient: OAD
	3 adult patients (20%)	c.787C>T c.864dupG c.1859C>T	p.Arg263Cys (1) p.Pro291Glnfs*51 (1) p.Thr620Ile (1)	17.9–19.6	21.5–61	124–219	7.2–9.5	1 patient: none; 2 patients: insulin
HNF1B (NM_000458.2)	2 pediatric patients (4.6%)	c.443 C>T c.827 G>A	p.Ser148Leu (1) p.Arg276Gln (1)	7.5–15.4	9.6–16.9	Not available	Not available	Insulin
Unknown (MODY X)	4 pediatric patients (9.3%)	—	—	4.5–12.8	7.8–16.5	106–252	5.6–7.8	1 patient: insulin; 3 patients: none
	9 adult patients (60%)	—	—	16.1–24.8	24–57.9	112–258	6.6–9.8	4 patients: insulin; 3 patients: insulin + OAD; 2 patients: OAD

OAD, oral antidiabetes drug. Reference sequences together with mutations nomenclature are reported according to the Human Gene Mutation Database Professional 2014.2. §Novel mutations cosegregating with hyperglycemia in each family not found in 396 alleles of nondiabetic individuals and 276 alleles of patients with type 2 diabetes. @Mutation predicted to be probably damaging by PolyPhen-2. #Deletion predicted to be probably damaging by MutationTaster.

Casarano, Italy), Adriana Franzese and Enza Mozzillo (Department of Pediatrics, University of Naples Federico II, Naples, Italy), and Dario Iafusco and Angela Zanfardino (Department of Pediatrics, Second University of Naples, Naples, Italy).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. M.D. and O.L. were in charge of diagnosis and follow-up of the patients. C.M., R.D.P., L.Z., A.M., V.G., and M.C. performed the genetic analysis. V.T. reviewed the manuscript and contributed to the data interpretation and discussion. F.B. conceived the study, wrote the draft, and contributed to the data interpretation and discussion. All the authors read and approved the final manuscript. M.D. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011;34:1878–1884

2. Lorini R, Klersy C, d'Annunzio G, et al.; Italian Society of Pediatric Endocrinology and Diabetology (ISPED) Study Group. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009;32:1864–1866

3. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504–2508

4. Gragnoli C, Cockburn BN, Chiaramonte F, et al. Early-onset type II diabetes mellitus in Italian families due to mutations in the genes encoding hepatic nuclear factor 1 alpha and glucokinase. Diabetologia 2001;44:1326–1329

5. Incani M, Cambuli VM, Cavalot F, et al. Clinical application of best practice guidelines for the genetic diagnosis of MODY2 and MODY3. Diabet Med 2010;27:1331–1333